Von Willebrand factor (VWF) is a multimeric protein that mediates platelet adhesion at sites of vascular injury, and ADAMTS13 (a disintegrin and metalloprotease with thrombospondin)is a multidomain metalloprotease that limits platelet adhesion by a feedback mechanism in which fluid shear stress induces proteolysis of VWF and prevents disseminated microvascular thrombosis. Cleavage of the Tyr 1605 -Met 1606 scissile bond in the VWF A2 domain depends on a Glu 1660 -Arg 1668 segment in the same domain and on the noncatalytic spacer domain of ADAMTS13, suggesting that extensive enzyme-substrate interactions facilitate substrate recognition. Based on mutagenesis and kinetic analysis, we find that the ADAMTS13 spacer domain binds to an exosite near the C terminus of the VWF A2 domain. Deleting the spacer domain from ADAMTS13 or deleting the exosite from the VWF substrate reduced the rate of cleavage Ϸ20-fold. A cleavage product containing the exosite was a hyperbolic mixed-type inhibitor of ADAMTS13 proteolysis of either VWF multimers or model peptide substrates but only if the ADAMTS13 enzyme contained the spacer domain. The specificity of this unique mechanism depends on tension-induced unfolding of the VWF A2 domain, which exposes the scissile bond and exosite for interaction with complementary sites on ADAMTS13.
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enzyme kinetics ͉ thrombotic thrombocytopenic purpura ͉ fluid shear stress A fter vascular injury, platelets adhere to von Willebrand factor (VWF), a multimeric blood protein that can exceed 20,000 kDa in mass. VWF mediates platelet adhesion to exposed connective tissue, endothelial cells, and other adherent platelets (1, 2) . To prevent thrombosis, platelet adhesion is regulated by a unique feedback mechanism involving tension-induced proteolysis. Flowing blood exerts a force on the growing platelet-rich thrombus that stretches VWF and exposes a cleavage site for plasma ADAMTS13, a member of a disintegrin and metalloprotease with thrombospondin type I repeat family (3) (4) (5) . The metalloprotease domain (M domain) of ADAMTS13 cleaves the Tyr 1605 -Met 1606 bond in the A2 domain of VWF (Pro 1480 -Gly 1672 , numbered from the initiation codon) (6) (7) (8) , severing the VWF multimer and releasing adherent platelets. ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura, a lifethreatening disease characterized by disseminated microvascular thrombosis (4, 9, 10) . Conversely, mutations in the VWF A2 domain that lead to excessive proteolysis cause von Willebrand disease type 2A, an inherited bleeding disorder (1) .
Achieving balanced regulation of platelet adhesion is a formidable challenge under the conditions prevailing in blood. VWF and ADAMTS13 occur at low concentrations of Ϸ10 g/ml and Ϸ1 g/ml, respectively, compared with the total plasma protein concentration of Ϸ80,000 g/ml. Nevertheless, VWF is the only known substrate of ADAMTS13 in plasma, even though ADAMTS13 is constitutively active (11) . Furthermore, VWF is resistant to AD-AMTS13 until it is subjected to high fluid shear stress (7), adsorbed onto a surface (12) , or treated with chaotropic agents such as urea (8) or guanidine hydrochloride (7) .
Several mechanisms contribute to the remarkable specificity of ADAMTS13. First, the activation of cleavage by tensile stress indicates that the scissile bond is inaccessible in native VWF. The modeled structure of the VWF A2 domain supports this conclusion, suggesting that the cleavage site is buried in a central ␤-sheet (13) and exposed on unfolding. Furthermore, von Willebrand disease mutations in the A2 domain that cause increased proteolysis are predicted to destabilize the folded structure (13) . Second, binding of platelet glycoprotein Ib␣ (GPIb␣) or heparin to the VWF A1 domain allosterically promotes cleavage of the adjacent A2 domain by ADAMTS13 (14, 15) . Finally, VWF cleavage is markedly impaired by deletion of the ADAMTS13 spacer domain (16, 17) or by deletion of residues E 1660 APDLVLQR 1668 from the VWF A2 domain (18) , suggesting that contacts between ''exosites'' on the enzyme and substrate, located some distance from the active site and scissile bond, facilitate substrate recognition. To date, these exosite interactions have not been characterized.
We now demonstrate by mutagenesis and kinetic analysis that the spacer domain of ADAMTS13 binds to an exosite at the C terminus of the VWF A2 domain that is separated by Ϸ50 aa residues from the cleaved Tyr 1605 -Met 1606 bond. This exosite appears to be cryptic in native VWF, and its interaction with the ADAMTS13 spacer domain is essential for feedback inhibition of VWF-dependent platelet adhesion. This elegant mechanism appears to be unique in its use of tension-induced conformational changes to expose cryptic exosites and cleavage sites, activating the proteolysis of VWF within platelet-rich thrombi in flowing blood and preventing microvascular thrombosis.
Results
Differential Cleavage of GST-VWF73 and GST-VWF64 by Plasma ADAMTS13. Variations in VWF unfolding complicate the analysis of ADAMTS13 enzyme kinetics, but cleavage can be studied independently of substrate unfolding with fragments of VWF domain A2 (18) that do not have significant secondary structure (19) . As reported in ref. 18 , a low concentration of plasma ADAMTS13 (Ϸ0.07 nM) cleaved GST-VWF73, which contains amino acid Author contributions: W.G., P.J.A., and J.E.S. designed research; W.G. and E.A.T. performed research; E.M.M. and E.A.T. contributed new reagents/analytic tools; W.G., P.J.A., and J.E.S. analyzed data; and W.G. and J.E.S. wrote the paper.
residues Asp 1596 -Arg 1668 from VWF domain A2 but not GST-VWF64, which lacks 9 aa residues (E 1660 APDLVLQR 1668 ) that are present at the C terminus of GST-VWF73. However, detectable cleavage of GST-VWF64 did occur on increasing the enzyme concentration 4-fold and increasing the reaction time from 2 h to 5 or 24 h (Fig. 1A) . Similar results were obtained in a buffer commonly used for ADAMTS13 assays (5 mM Tris⅐HCl, pH 8.0/10 mM BaCl 2 ) (18) and in a more physiological buffer with optimized divalent metal ion concentrations (50 mM Hepes, pH 7.4/150 mM NaCl/5 mM CaCl 2 /0.1 M ZnCl 2 ) (20) . GST-VWF64 preparations with and without a C-terminal His 6 tag were cleaved at similar rates (data not shown), indicating that slow cleavage is attributable to the absence of the amino acid residues Glu 1660 -Arg 1668 and not to relocation of the His 6 tag.
Cleavage of GST-VWF73 and GST-VWF64 by Recombinant ADAMTS13
Variants. Molecular modeling suggests that the critical amino acids missing from VWF64 comprise a C-terminal ␣-helix in the VWF A2 domain (13) , which could provide an exosite for substrate recognition by ADAMTS13. Deletion of the ADAMTS13 spacer domain also markedly impairs the cleavage of VWF (16, 17) , suggesting that the spacer domain might bind such an exosite. To assess this potential interaction, recombinant ADAMTS13 and selected variants (Fig. 1B) were compared for activity with the substrates GST-VWF73 and GST-VWF64.
When used at the concentration of plasma ADAMTS13 (3 nM), all recombinant forms of ADAMTS13 except for the isolated metalloprotease domain (M) cleaved both GST-VWF73 and GST-VWF64 during a 5-h reaction ( Fig. 2A) . The M construct also did not cleave either substrate when reactions were extended to 24 h and the enzyme concentration was increased to 30 nM (Fig. 2B) . No aberrant cleavage products were observed for any construct, and EDTA blocked cleavage completely. The amino acid sequence of the C-terminal GST-VWF64 cleavage product, determined by Edman degradation, began with MVTGNPASD. Thus, ADAMTS13 cleaves the Tyr 1605 -Met 1606 bond in GST-VWF64, GST-VWF73 (21), and plasma VWF (6) (7) (8) .
The ADAMTS13 Spacer Domain Accelerates GST-VWF73 Cleavage. In preliminary studies by an ELISA method (22) , the reaction rate depended on specific domains of ADAMTS13, which differed for the two substrates. GST-VWF73 was cleaved Ϸ60% in 30 min by full-length ADAMTS13 and even more rapidly by construct MDTCS. Deletion of the spacer domain markedly decreased the cleavage rate, and construct M was inactive (Fig. 3A) . As expected, GST-VWF64 was cleaved slowly by full-length ADAMTS13. The largest differences in rate were attributable to the spacer domain. In particular, MDTCS cleaved GST-VWF73 Ͼ8-fold faster than GST-VWF64, whereas MDTC cleaved both substrates at the same rate.
Kinetics of VWF73 and VWF64 Cleavage. A quantitative mass spectrometry assay was developed to evaluate the role of the ADAMTS13 spacer domain and the C-terminal Glu 1660 -Arg 1668 segment of VWF domain A2 in substrate recognition. Substrates VWF73 and VWF64 were prepared by digesting GST-VWF73 and GST-VWF64, respectively, with rhinovirus 3C protease to remove the GST moiety. Subsequent cleavage by ADAMTS13 released a small N-terminal 1,615-Da product peptide that was detected by MALDI-TOF MS. The amount of product was determined with reference to an internal standard peptide identical in sequence but with 7 Da greater mass resulting from isotopic substitution (Fig. 3B) . The assay was linear over the 2.5- 250-fmol product, and the interassay coefficient of variation was 8.5% (n ϭ 12). With this assay, kinetic constants were determined for fulllength ADAMTS13, MDTCS, and MDTC ( Fig. 3C and If so, the C-terminal cleavage product of VWF73 (cVWF63) would be expected to inhibit MDTCS but not MDTC, which lacks a spacer domain. When tested at a fixed concentration (7.5 M), cVWF63 did inhibit MDTCS activity toward either substrate VWF73 or VWF64 (1.5 M) by Ͼ82%, but it had no effect on the activity of MDTC (Table 2) . Product cVWF63 also inhibited ADAMTS13 and MDTCS cleavage of multimeric plasma VWF by 73-78%, but it inhibited MDTC Ͻ10% (Fig. 4A) , demonstrating a role for the ADAMTS13 spacer in recognizing full-length VWF as well as model peptide substrates.
Kinetic analysis (Fig. 4B) showed that product cVWF63 inhibited the cleavage of VWF73 in a manner consistent with mixed-type inhibition of enzyme MDTCS (Fig. 4C ). In this model, the inhibitor cVWF63 binds through an exosite interaction to the enzyme MDTCS with a K i of 0.44 Ϯ 0.11 M and to the MDTCS-VWF73 complex with ␣K i of 2.4 Ϯ 1.1 M, where the errors represent the SD for the global fit of the data to Eq. 1 (see Methods). Similarly, substrate VWF73 binds to MDTCS with a K s of 0.77 Ϯ 0.11 M and to the complex of MDTCS and cVWF63 with ␣K s of 4.3 Ϯ 1.8 M. The MDTCS-VWF73 enzyme-substrate complex yields product at a rate k cat of 1.7 Ϯ 0.05 s Ϫ1 . The ternary cVWF63-MDTCS-VWF73 inhibitorenzyme-substrate complex yields product at a much slower rate that approaches zero at sufficiently high concentrations of cVWF63 (␤k cat of 0.2 Ϯ 0.2 s Ϫ1 ). This exosite-dependent mechanism accounts for the observed kinetics of product inhibition and for the dependence of reaction rates on both the Glu 1660 -Arg 1668 segment of VWF73 and the ADAMTS13 spacer domain.
Discussion
The balanced regulation of VWF cleavage in vivo depends on several cooperative interactions with ADAMTS13. The metalloprotease domain of ADAMTS13 must recognize and cleave (Figs. 2 and 3 ) (23), suggesting that the disintegrin domain may help to position the substrate in the active site. In addition, removal of the spacer (e.g., construct MDTC) markedly impairs substrate cleavage, whereas constructs containing the spacer domain (e.g., MDTCS) cleave multimeric VWF, GST-VWF73 (Fig. 3A) , or VWF73 ( Fig. 3C and Table 1 ) at essentially a normal rate (16, 17, 23) . Therefore, the spacer domain is a major determinant of catalytic efficiency.
ADAMTS13 binds with high affinity and cleaves either multimeric VWF or GST-VWF73, provided the spacer domain is present (12, 23) . Therefore, the structural requirements for ADAMTS13 to cleave small substrates like VWF73 are similar to those for cleaving multimeric VWF, which implies that interactions limited to the A2 domain are sufficient to determine the substrate specificity of ADAMTS13. Furthermore, our kinetic data, particularly the effects of product inhibition (Fig. 4 and Table 2 ), indicate that the ADAMTS13 spacer domain binds to an exosite within VWF domain A2 that is distant from the scissile bond and requires residues Glu 1660 -Arg 1668 . Disruption of this exosite in the VWF substrate or deletion of the spacer domain from ADAMTS13 causes a similar marked reduction in the rate of substrate cleavage. In addition, ADAMTS13 does not bind native multimeric VWF unless it is treated with chaotropic agents or adsorbed to a surface (12) , suggesting that the exosite, like the scissile bond, is buried within the folded A2 domain.
At maximum extension, the distance between the scissile bond (Tyr 1605 -Met 1606 ) and the exosite (up to Arg 1668 ) could be as much as 220 Å (3.5 Å per residue), and ADAMTS13 appears able to accommodate a substrate of this length. For example, a combination of a metalloprotease domain [ADAM33, protein data base (PDB) ID code 1R54; Ϸ26 ϫ Ϸ38 ϫ Ϸ52 Å] (24), a disintegrin (trimestatin, PDB ID code 1J2L; Ϸ15 ϫ Ϸ22 ϫ Ϸ48 Å) (25) , and a TSP1 repeat (PDB ID code 1LSL; Ϸ15 ϫ Ϸ20 ϫ Ϸ55 Å) (26) might span Ϸ150 Å. The Cys-rich and spacer domains, comprising 246 aa residues and 27.5 kDa, would complete the substrate binding surface. ADAMTS13 domains between the metalloprotease and spacer presumably would interact with VWF domain A2 sequences between the scissile bond and exosite, and the first TSP1 repeat is a likely candidate based on the effects of mutagenesis. Deletion of the ADAMTS13 spacer increases the K d for binding immobilized VWF from Ϸ14 nM to Ϸ200 nM, and further deletion of the first TSP1 domain abolishes specific binding (12) .
Structures other than the proximal ADAMTS13 domains and the VWF A2 domain also contribute to the regulation of VWF proteolysis. Deletion of the C-terminal TSP1 repeats and CUB domains has small but significant effects on binding affinity for multimeric VWF (12) and on the cleavage of both VWF73 and VWF64 ( Table 1 ), suggesting that distal ADAMTS13 domains can influence the recognition of substrates by more proximal domains. The VWF A3 domain, just C-terminal to the homologous A2 domain, also may bind to the CUB domains of ADAMTS13 and help to localize it in flowing blood (27, 28) , although the VWF A3 domain has no effect on substrate cleavage under static conditions (14, 15, 29) .
The VWF A1 domain regulates ADAMTS13 through yet another mechanism, by providing a docking site for activating cofactors. We have shown that VWF domain A1 inhibits the cleavage of the adjacent domain A2, and this inhibition can be alleviated by the interaction of domain A1 with platelet GPIb␣ or glycosaminoglycans (14) . A recent study also shows that VWF domain A1 binds chloride ions, which inhibits the cleavage of the Tyr 1605 -Met 1606 bond in domain A2 by ADAMTS13 (15) . In addition, the conformation of domain A1 changes when it binds to GPIb␣, and a VWD type 2B mutation within the A1 domain that stabilizes this bound structure reduces chloride binding and accelerates the cleavage of the adjacent A2 domain (15) . Thus, cofactor binding to VWF domain A1 appears to modify the A2 domain allosterically, promoting the exposure of its cryptic scissile bond and exosite to ADAMTS13. Initial cleavage rates without (Ϫ) and with (ϩ) 7.5 M cVWF63. The concentration of substrate was 1.5 M. Values are the mean Ϯ SD for at least three independent experiments.
Our findings, together with results from several other approaches, support a model for regulating platelet adhesion primarily by tension-activated proteolysis. Membrane GPIb␣ on adherent platelets binds to the A1 domain of VWF, and this interaction allosterically destabilizes the adjacent domain A2 (14, 15) . In addition, fluid shear stress in flowing blood acts on the adherent platelets and applies tensile stress to the VWF multimers, which unfolds the A2 domain and exposes the Tyr 1605 -Met 1606 bond to the ADAMTS13 active site (7, 13) as well as a C-terminal exosite for binding to the ADAMTS13 spacer domain (12, 16, 17, 23) . ADAMTS13 severs the VWF multimer, releasing the adherent platelets and limiting thrombus growth. These cooperative interactions between the active site and exosite limit the action of ADAMTS13 in time and space, confining it to platelet-rich thrombi that experience enough fluid shear stress. The physiologic importance of the VWF exosite-ADAMTS13 spacer interaction is emphasized by the finding that autoantibodies to the spacer domain inhibit ADAMTS13 and are common causes of thrombotic thrombocytopenic purpura (17, 30, 31) .
The VWF-ADAMTS13 system appears to be unique in its use of tension-induced protein unfolding as the signal for biologically essential feedback inhibition, in this case mediated by proteolysis. However, similar mechanisms might evolve wherever tension on a protein sensor could expose cleavage sites or exosites to a suitable protease. Such a mechanism is particularly appropriate to the circulatory system, where pathologically increased fluid shear stress is characteristic of injured blood vessels that are in danger of thrombotic occlusion.
Methods
Preparation of ADAMTS13 Substrates. Plasmids were constructed as described in ref. 18 to express proteins composed of Schistosoma japonicum GST, a cleavage site for human rhinovirus 3C protease, a segment of VWF domain A2, and a C-terminal His 6 tag. The desired VWF coding sequence was amplified by PCR using the template pSVHvWF1 (32) , Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA), and appropriate oligonucleotide primers (18) . PCR products were inserted between the BamHI and EcoRI sites of plasmid pGEX-6P-1 (Amersham Biosciences, Piscataway, NJ). Plasmid pGST-VWF73 encodes VWF residues Asp 1596 -Arg 1668 , and plasmid pGST-VWF64 encodes VWF residues Asp 1596 -Arg 1659 . GST-VWF73 and GST-VWF64 were expressed in Escherichia coli BL21 (18) . Bacteria were grown to log phase in LB medium at 37°C and induced for 4 h with 0.25 mM isopropyl ␤-Dthiogalactoside. Cells were harvested, and soluble fractions were prepared by using CelLytic B (Sigma, St. Louis, MO). Proteins from a 0.8-liter culture were adsorbed onto 3 ml of Ni 2ϩ -nitrilotriacetic acid-agarose beads (Qiagen, Valencia, CA) and eluted with 50 mM sodium phosphate, pH 8.0/250 mM imidazole. Proteins were dialyzed against 20 mM Tris⅐HCl, pH 8.0/150 mM NaCl, adsorbed onto a 2-ml column of glutathione-agarose (Amersham Biosciences), and eluted with buffer containing 10 mM glutathione. After dialysis against 20 mM Tris⅐HCl, pH 8.0/150 mM NaCl, the protein concentration was determined with a BCA protein assay kit (Pierce, Rockford, IL) and a BSA standard.
To obtain VWF73 and VWF64 peptides, GST-VWF73 and GST-VWF64 were cleaved with PreScission protease (Amersham Biosciences) at 2 units of enzyme per 100 g of substrate for 10 h at 4°C. PreScission protease and released GST were removed by adsorption onto 2 ml of glutathione-agarose. Products in the supernatant were purified by HPLC on a C 18 column (10 ϫ 150 mm 218TP; Vydac, Hesperia, CA) with an acetonitrile gradient (0-80%) in 0.1% trifluoroacetic acid. Peptides were concentrated by using vacuum and dialyzed against 50 mM Hepes, pH 7.4/150 mM NaCl. Peptide concentrations were determined by amino acid analysis and absorbance at 280 nm. Substrates were stored at Ϫ80°C. Cleavage of GST-VWF73 or GST-VWF64 was initiated by adding 1 l or 4 l, respectively, of citrated normal human plasma and buffer sufficient to make a total volume of 45 l. Reactions were incubated at 37°C for 2 h, 5 h, or 24 h and stopped by adding an equal volume of 2ϫ SDS sample buffer containing 30 mM EDTA. Samples (10 l) were analyzed by SDS/PAGE on 10-20% gradient gels (Invitrogen), electrotransfer onto PVDF membranes, and incubation with a 1:10,000 dilution of horseradish peroxidase-conjugated rabbit anti-GST (Amersham Biosciences). Bands were detected by chemifluorescence (ECL Plus). Reactions with recombinant ADAMTS13 or variants were performed similarly by using reaction buffer B, substrate concentration of 3 or 30 nM, and an incubation time of 5 h or 24 h.
Alternatively, an ELISA method was used (22) with minor modification. Microtiter plates precoated with anti-GST antibodies (Pierce) were incubated 1 h at room temperature with GST-VWF73 or GST-VWF64 (0.25 g/ml). After washing, ADAMTS13 or a variant (3 nM) in reaction buffer B (50 l) was added and incubated at 37°C for different times. After three washes, the remaining uncleaved substrates were detected with horseradish peroxidase-conjugated anti-His antibodies (Invitrogen) or Indian His-Pro (Pierce) for 1 h at room temperature. Plates were developed by an illumination kit (Pierce) and read at 450 nm.
Cleavage Site Characterization. GST-VWF64 (5 g) was incubated in reaction buffer B with recombinant ADAMTS13 (30 nM) at 37°C for 5 h. Components were separated by SDS/PAGE on a 10-20% gradient gel, transferred onto a PVDF membrane (Bio-Rad, Hercules, CA), and stained with SimplyBlue SafeStain (Invitrogen). The 7.0-kDa product band was excised and sequenced by automated Edman degradation (Protein and Nucleic Acid Laboratory, Washington University).
Kinetics Studies by MALDI-TOF MS.
Reactions were performed at room temperature (25°C) in reaction buffer B containing varying concentrations of VWF73 or VWF64, and ADAMTS13 or a variant (0.056 nM enzyme for VWF73 cleavage or 0.28 nM enzyme for VWF64 cleavage). Reactions were desalted by adsorption on C18 micropipette tips (Glygen Corp., Columbia, MD) and elution with 60% acetonitrile/0.1% formic acid. Samples (1 l) were mixed with 250 fmol (1 l) of synthetic peptide standard (Sigma) having leucine at position 3 isotopically labeled with 13 C and 15 N (GP ([  13 C 15 N]L)GSDREQAPNLVY; mass, 1,622). Aliquots (0.5 l) were mixed with an equal volume of ␣-cyano-4-hydroxycinnamic acid matrix (6.2 mg/ml in methanol/ acetonitrile/water ϭ 36/56/8; Agilent Technologies, Santa Clara, CA) and analyzed by MALDI-TOF MS (33) . Linearity of the assay was confirmed by constructing standard curves with a similar product peptide (CDREQAPNLVY; mass, 1,307) and the standard peptide. Synthetic peptide concentrations were determined by amino acid analysis. Initial rates of product generation were determined by sampling reactions at five to seven time points between 0 and 30 min (Ͻ8% substrate cleavage) and linear regression analysis. Rates were fitted to the Michaelis-Menten equation to obtain the apparent Michaelis constant (K m ) and catalytic rate constant (k cat ).
Inhibition of Substrate Cleavage by Product cVWF63. GST-VWF73 (8 mg) was digested to completion by recombinant ADAMTS13 (0.3 nM) in buffer B (10 ml) for 5 h at 37°C. The C-terminal 63-aa residue product peptide (cVWF63) was purified by HPLC as described for VWF73. To assess product inhibition, reactions were performed in buffer B with varying concentrations of cVWF63, VWF73, or VWF64, and ADAMTS13 or variants. Initial rates were determined by MALDI-TOF MS analysis. Product generation as a function of enzyme (E), cVWF63 (I), and substrate (S) were analyzed according to a general model in which cVWF63 is a hyperbolic mixed-type inhibitor of AD-AMTS13 (34) as shown in Fig. 4C Cleavage of plasma VWF by ADAMTS13, MDTCS, or MDTC was assayed in reaction buffer B by Western blotting and densitometry of the 350-kDa dimer of C-terminal VWF subunit fragments (7, 20) in the presence or absence of cVWF63.
